Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomised Study to Investigate FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab as First-line Treatment of BRAF-mutated Metastatic Colorectal Cancer

NCT04034459 is registered in ClinicalTrials.gov with Ludwig-Maximilians - University of Munich as lead sponsor.

NCT NCT04034459
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04034459 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomised Study to Investigate FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab as First-line Treatment of BRAF-mutated Metastatic Colorectal Cancer
Lead sponsor
Ludwig-Maximilians - University of Munich
Phase
Phase 2
Overall status
Unknown status
Start date
November 25, 2016
Completion date
December 31, 2023
Enrollment
109 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer